An open-label Phase 2 trial to investigate efficacy and safety of intra-amniotic administrations of ER004 in male subjects with X-linked hypohidrotic ectodermal dysplasia (XLHED)

We invite you to take part in a research study

Before you decide whether to take part, it is important for you to understand why the research is being done and what it will involve.

This leaflet is meant to explain to you what the EDELIFE study is about and what commitment it will require from you.
Important things that you need to know about the EDELIFE study

We want to try and find a treatment for boys affected by XLHED.

We are conducting a study on a treatment called ER004, an experimental medicine. ER004 has been created to replace a protein that is missing in those affected by XLHED. ER004 will be given before birth. The study is being conducted in several centres in Europe and the US. In the US, there will be two centres open, in UCSF (San Francisco, California) and in Washington University (St Louis, Missouri).

You are being asked to participate in this study because:

1. You are pregnant with a boy and your unborn son is affected with XLHED
   - The treatment will be given to your unborn son at pregnancy weeks 26, 28-29 and 31-32.
   - No treatment will take place after he is born.
   - Your son will remain in the study for follow up checks for 5 years after his birth, to understand the full effects of the treatment.
   - This study will come on top of your normal pregnancy care and will require study-specific visits to San Francisco or St Louis.

2. You are an XLHED male relative of a pregnant woman whose unborn son is affected with XLHED and who is participating in the study:
   - Your participation in the study is required for 1 visit only, to gather data on your XLHED symptoms

3. Why are we doing this study?
4. Who can take part in the study?
5. What do I need to know about the experimental medicine, ER004, and the procedure to give it?
6. I am a pregnant woman: what will I need to do if I decide to take part?
7. What are the possible side effects of the treatment?
8. Things to consider before deciding to participate in the study for pregnant women
9. I am a XLHED-affected male blood relative of a pregnant woman who is participating in the study:
   - Your participation in the study is required for 1 visit only, to gather data on your XLHED symptoms

More information about taking part

How to contact us

If anything is unclear or if you have any questions about this study, please talk to the study doctors in charge of the study,

Dr Mary Norton
Mary.Norton@ucsf.edu

or Dr Dorothy Grange
grangedk@wustl.edu

or contact Mary Fete, from the USA ED association, the NFED: mary@nfed.org
1. **Why are we doing this study?**

As you know, there is currently no treatment for XLHED. Pierre Fabre and the EspeRare Foundation, known as the Sponsors* of the study, are conducting a research study or clinical study*, called EDELIFE, on the safety* and possible health benefits of an experimental medicine for XLHED called ER004*. Previous, three XLHED-affected boys received the ER004 treatment before birth (prenatal treatment*). After birth, all three babies showed improvement in some symptoms, particularly regarding their ability to sweat. These results have been reported in a scientific journal (N Engl J Med 2018; 378:1604-1610). These prenatal treatments using ER004 indicated the potential of this experimental medicine to prevent or at least significantly reduce the severity of some XLHED symptoms. We now want to confirm these preliminary results in a robust clinical study, with 2 aims:

- We want to find out if prenatal treatment with ER004 is well tolerated
- We want to find out if prenatal treatment with ER004 can lead to a long-lasting improvement of some symptoms in XLHED-affected boys

If successful, this study could lead to ER004 being approved as the first commercially available treatment for XLHED.

2. **Who can take part in the study?**

These two groups will help us to better evaluate and quantify the effects of the treatment by comparing data collected from the boys who have received ER004 with the data collected from XLHED-affected males who have not received ER004. If a male blood relative cannot be included in the study, we will use existing and previously collected data for the comparison.

There are two different profiles of participants we are looking for in our EDELIFE study:

- **The treated subjects group***:
  - We need approximately 20 participants* to take part in our study and who will be treated with ER004. This “treated subjects group” will be made up of pregnant women with a confirmed genetic diagnosis* of XLHED, and who will be expecting a baby boy.

- **The comparator (comparison, or control) group***:
  - We also need 20 participants who are XLHED-affected male blood relatives of the pregnant women to form a “comparator group”. This group will not be treated with ER004.

**You are being asked to take part in this study because:**

- You are a pregnant woman (aged 18 or over), with a confirmed genetic diagnosis of XLHED, you are expecting a boy and your unborn son might be affected by XLHED. As the treatment is to be given to your XLHED-affected son before he is born, you, as the pregnant woman, are being asked to participate in this study and agree to the treatment of your son whilst in your womb.
  We will ask you for the contact details of an XLHED-affected male blood relative of yours who would be willing to participate in the comparator group. If you do not have this information or if your relative is unable to participate, this should not affect your participation in this study as comparator data may be obtained from other sources.

- You are an XLHED-affected male blood relative of a pregnant woman whose son will be treated in the study
  You will not receive any treatment if you decide to take part in this study. However, your participation in the comparator group* is crucial for the success of this study as we need to gather data from non-treated XLHED males to demonstrate whether or not the treatment has worked.

*See Glossary p.16
What is ER004?

ER004 is an experimental medicine*. It is not approved for use except in clinical studies and is not available for sale. It is hoped ER004 will replace an important protein called EDA (Ectodysplasin-A) which is missing in those affected by XLHED. Absence of this protein during the baby’s development in the womb leads to some important structures not forming properly (sweat glands, hair, teeth etc). When given to XLHED-affected baby boys at the right time in the womb, ER004 should act as a replacement for the missing EDA and trigger the process that leads to the normal development of a baby’s skin, teeth, hair, and sweat glands, leading to better formation of these structures.

Giving ER004 to your baby while still in the womb might sound scary. However, we think this is the only time at which the treatment might work. You may remember that Edimer Pharmaceuticals, who previously developed the treatment, conducted a research study giving ER004 to affected newborn babies in the first fourteen days of life. While ER004 did not lead to any major or significant side effects, it did not work on improving XLHED symptoms. We now understand that replacing the missing EDA protein with ER004 after birth came too late as the development of the structures had already occurred. Therefore, for the replacement ER004 to have a chance to work, it must be given during the development of the important structures (sweat glands, hair, teeth etc.), before birth.
4. I am a pregnant woman: what will I need to do if I decide to take part?

(if you are a male relative of the pregnant woman, you can skip this part and go directly to part 7)

For pregnant women receiving the treatment, the study is divided into 3 parts:

- **A Screening** period
- **A Treatment** period
- **A Follow-up** period

Below is a graphical representation of the study, its different phases, the different visits and how long they take:

If you choose to participate in this study, you will be asked to come to visits to the clinical site in San Francisco or in St Louis for each study period. It is also recommended that you give birth in these sites. Altogether, there will be 14 visits over 5 years.

The screening period:

- The screening consists of 1 visit to the clinical site in San Francisco or in St Louis. This visit is anticipated to take half a day to a full day and must take place between pregnancy week 19 and the end of week 24.
- This visit will confirm that you are carrying a boy. The study team will check if your unborn son is affected or not by XLHED using a non-invasive ultrasound* scan.
- The doctors will take a blood sample and conduct a series of other, non-invasive medical tests on you, to ascertain whether you and your unborn son can participate in the study (i.e. decide whether you are eligible*).
- You will get a chance to discuss the study in person with the Principal Investigator, the doctor responsible for the study, or his deputy.

Below is a graphical illustration of the panel of tests that you will undergo at the Screening visit:

If you are eligible* and choose to participate in the study, you will come back later for treatment of your unborn son.

If you do not choose to participate or if you are not eligible, you will not be asked to come back to the centre for the study. Please be reassured that your medical care will not be affected by this decision.

*See Glossary p.16
The treatment period:

- Treatment for your unborn child will take place at the San Francisco or the St Louis site over 3 visits, approximately 3 weeks apart, at pregnancy weeks 26, 28-29 and 31-32.
- At each visit, you will receive one ER004 injection. Each visit will require you to attend the site for 2 days. Before each injection, a health check for both you and your baby will be conducted, to ensure all is well and you can receive the treatment. After the injection, you will rest and be required to spend the night on site for observation.
- At the first treatment visit, we will ask you to have an MRI scan*. This is to assess the tooth development of your baby before ER004 treatment. The procedure is not generally considered to be painful, but the machine makes a loud noise. The procedure should not last more than 90 minutes.
- As part of the first treatment visit, we will ask to interview you. This interview will be conducted remotely and you will not need to go to the San Francisco or the St Louis site for this. This interview will be conducted by a trained interviewer, the aim of which is to hear your viewpoints, experiences, feelings and opinions on XLHED and the ER004 treatment. This interview is recorded (audio only) and should not last longer than 25 minutes.
- No treatment will take place after your baby is born.

Below is a graphical illustration of the procedures that you will undergo at a Treatment visit

Follow-up:

The follow-up period starts with the birth of your child and will last until your son is 5 years old.

After delivery, you will be asked to come to the clinical site for 9 more visits, with your son.

Medical examinations of your son will allow us to evaluate if the treatment has worked and how safe it is.
- Each visit will last between a half and a full day. Slightly different tests will be conducted at different visits.
- At these follow-up visits, your son will undergo many tests to check his XLHED symptoms and make sure he is doing well. These tests are all non-invasive.
- The doctors will take a blood sample from your son on 3 separate follow up visits. Analysing your son’s blood will show very important information on how well your son has coped with the treatment. Altogether, the blood volume taken over these 3 visits will represent less than a teaspoon (5 mL). Blood will be drawn by a trained professional who is used to dealing with small infants.

*See Glossary p.16
• It is important to assess the outcome of the treatment on your son’s tooth growth and his teeth will be examined at each visit.
  – One MRI assessment is planned between the ages of 3 and 6 months. For this, your son will not require sedation. Throughout this procedure, you will remain next to your son. The procedure is not generally considered to be painful, but the machine makes a loud noise. The whole procedure should take no more than 90 minutes.
  – One X-ray will be taken between 36 and 60 months of age.
• At some visits, you will be asked to fill in questionnaires about your and your son’s quality of life. This should take no longer than 40 minutes.
• As mentioned in the treatment period, we will ask to interview you again. These interviews will be conducted in the same way as during the treatment period. Your child does not need to be present. This interview is recorded (audio only) and should take no longer than 40 minutes.
• You will also undergo some tests, but only at delivery and at the follow-up visit immediately after delivery, to ensure your health has not been affected by your son’s treatment.

Below is a graphical illustration of the panel of tests that your son will undergo at a typical Follow-up visit.

5. What are the possible side effects of the treatment?

Side effects can come from the experimental medicine, ER004, and from the injection procedure itself. If you would like more information on the potential risks associated with ER004 injection, please ask the study doctor.

• So far, ER004 has not been found to have any major significant undesirable side effects, but it is a product in development and may therefore have unknown side effects. You will be informed about this later on if you decide to participate in the study.
• The injection procedure is like an amniocentesis, and we think the risks associated with it are the same. Complications range from mild discomfort at the point of injection to early delivery of your baby, and the potentially serious ensuing health issues for him because of preterm birth. These risks and how likely they are to occur will be made clear to you later on.

6. Things to consider before deciding to participate in the study for pregnant women

• Pregnant women who think they match the inclusion criteria but live in a country where there is no study centre opened may be able to take part in the study regardless and are therefore strongly encouraged to reach out to the Coordinator investigator, prof Holm Schneider.
• You will need to have a genetic confirmation of your XLHED carrier status to be able to participate in the study. If you are unsure about this, please contact your GP or clinical geneticist, who should be able to help you with this requirement.
• Please be advised that the procedures and tests you will undergo as part of the study do not in any way replace your standard pregnancy care, which will need to carry on as usual. Study visits come on top of all other routine medical care.
If you do choose not to participate, your involvement in the study will end and we will not contact you again. Please be reassured that your medical care will not be affected by this decision. If you choose to participate in the study, you will come for one visit to the medical site in San Francisco or St Louis.

- This visit will take between a half and a full day
- Medical tests will be conducted on you. Most of these tests are non-invasive and should not lead to any major discomfort for you, but a blood sample may be required to confirm the XLHED mutation.

What if I don’t want to participate anymore? Please remember that you have the right to decide, at any point during the study, not to participate any longer, even if you had initially chosen to participate. This decision will not affect the medical care you receive in any way.

You will be asked to come to the clinical site in San Francisco or St Louis for one visit only. This visit must take place before the treated baby reaches 6 months of age. Before the visit, the medical team at San Francisco or St Louis will have shared with you more detailed information about the study to help you decide whether or not to participate.

To participate, you must be aged between 6-months and 60 years old and must be a XLHED-affected blood relative of the pregnant woman. You must not have been treated with ER004 previously.

You will be asked to come to the clinical site in San Francisco or St Louis for one visit only. This visit must take place before the treated baby reaches 6 months of age. Before the visit, the medical team at San Francisco or St Louis will have shared with you more detailed information about the study to help you decide whether or not to participate.

This visit will take between a half and a full day

Medical tests will be conducted on you. Most of these tests are non-invasive and should not lead to any major discomfort for you, but a blood sample may be required to confirm the XLHED mutation.

Below is a graphical illustration of the panel of tests that you will undergo when you come for your visit
8. More information about taking part

If you are interested in the study, please contact Dr Mary Norton (San Francisco) or Dr Dorothy Grange (St Louis), the doctors responsible for the study in the US, who will then share more information with you on the study, including, should you wish to, the full Information Sheet that details the whole study.

Please take all the time you need to reflect before the Screening visit. If it helps, discuss the study with your family, friends or medical team (midwife, GP etc) before giving your consent or deciding not to participate.

At the Screening visit, you will get a chance to discuss in person the study with Dr Norton or Dr Grange. It might be a good idea that you prepare and have ready some written questions.

EDELIFE clinical trial website:  https://edelifeclinicaltrial.com/
clinical trials information:  https://clinicaltrials.gov/ct2/show/NCT04980638?term=EDELIFE&draw=2&rank=1
<table>
<thead>
<tr>
<th><strong>Glossary</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ultrasound</strong></td>
</tr>
<tr>
<td><strong>MRI</strong></td>
</tr>
<tr>
<td><strong>Treated subject group</strong></td>
</tr>
<tr>
<td><strong>Comparator group</strong></td>
</tr>
<tr>
<td><strong>Screening</strong></td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
</tr>
<tr>
<td><strong>Follow-up</strong></td>
</tr>
<tr>
<td><strong>Eligible</strong></td>
</tr>
<tr>
<td><strong>Prenatal treatment</strong></td>
</tr>
<tr>
<td><strong>Amniocentesis</strong></td>
</tr>
</tbody>
</table>
If you would like more information about the EDELIFE study, please contact the study doctor for this study in the USA, Dr. med Mary E Norton in San Francisco (mary.norton@ucsf.edu) and Dr. med Dorothy Katherine Grange in St Louis (grangedk@wustl.edu) or contact Mary (mary@nfed.org), the National Foundation for Ectodermal Dysplasias representative (www.nfed.org)